Partner Headlines - ALKS

  1. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  2. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  3. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  4. Alkermes' drug passes trial

    IBD
  5. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  6. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  7. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  8. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  9. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  10. Benzinga's Volume Movers

    Benzinga
  11. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  12. Morning Market Movers

    Benzinga
  13. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  14. Benzinga's Top Initiations

    Benzinga
  15. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  16. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  17. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  18. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  19. Stocks End Short Week With Big Losses

    IBD
  20. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  21. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  22. Ireland Home To Several Fast Growing Health Care Names

    IBD
  23. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  24. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  25. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  26. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  27. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  28. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  29. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  30. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  31. Alkermes

    IBD
  32. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  33. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  34. Alkermes

    IBD
  35. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  36. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  37. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  38. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  39. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  40. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  41. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  42. Stocks Pare Early Losses, End With Modest Declines

    IBD
  43. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  44. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  45. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  46. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  47. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  48. Dow Leads Market Higher As Volume Swells

    IBD
  49. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  50. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  51. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  52. Stocks Tumble On Disappointing Earnings Reports

    IBD
  53. Why Cisco, Google And Apple All Became Big Winners

    IBD
  54. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  55. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  56. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  57. Alkermes Writes New Prescription For Growth

    IBD
  58. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  59. Health Care Sector Wrap

    FoxBusiness
  60. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  61. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  62. Elan

    IBD
  63. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  64. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  65. Market Roundup

    Benzinga
  66. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  67. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  68. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  69. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  70. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  71. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  72. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  73. Benzinga's Top Pre-Market Gainers

    Benzinga
  74. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  75. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  76. Benzinga's Volume Gainers

    Benzinga
  77. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  78. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
  79. Top-Performing Fund Managers Tap Retail, Food Stocks

    IBD
  80. Positive Data Lifts Stocks in Early Trading

    MarketIntelligenceCenter
  81. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
Trading Center